JP2024029735A - Medicine for alleviating health issues caused by crowds - Google Patents

Medicine for alleviating health issues caused by crowds Download PDF

Info

Publication number
JP2024029735A
JP2024029735A JP2022201857A JP2022201857A JP2024029735A JP 2024029735 A JP2024029735 A JP 2024029735A JP 2022201857 A JP2022201857 A JP 2022201857A JP 2022201857 A JP2022201857 A JP 2022201857A JP 2024029735 A JP2024029735 A JP 2024029735A
Authority
JP
Japan
Prior art keywords
crowd
extract
medicine
crowded
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022201857A
Other languages
Japanese (ja)
Inventor
愛美 植田
Manami Ueda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kobayashi Pharmaceutical Co Ltd
Original Assignee
Kobayashi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kobayashi Pharmaceutical Co Ltd filed Critical Kobayashi Pharmaceutical Co Ltd
Priority to JP2022201857A priority Critical patent/JP2024029735A/en
Publication of JP2024029735A publication Critical patent/JP2024029735A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

PROBLEM TO BE SOLVED: To provide an oral medicine that can alleviate health issues caused by crowds.
SOLUTION: A medicine for alleviating health issues caused by crowds comprises ryokei-jutsukan-to extract as an active ingredient.
SELECTED DRAWING: None
COPYRIGHT: (C)2024,JPO&INPIT

Description

本発明は、人混み不調改善薬に関する。 TECHNICAL FIELD The present invention relates to a medicine for improving crowd disorder.

満員電車、繁華街、イベント会場等の、人が密集している(以下において、「人混み」と記載する。)環境は、当該環境に特有の刺激を人にもたらす。そのような刺激は、感受性が高い等の特性を持つ人に対して様々な不調を誘発する。 BACKGROUND ART Environments where people are densely packed (hereinafter referred to as "crowds"), such as crowded trains, downtown areas, and event venues, bring stimulation unique to the environment to people. Such stimuli induce various disorders in people who have characteristics such as high sensitivity.

具体的には、人混み環境がもたらす刺激としては、自らのパーソナルスペース内に他人が接近し、場合によっては更に他人が行き交うことによる緊張刺激;多くの他人が視界に入り、且つ場合によっては更に他人が行き交うことで視線の動きを強要されることによる視界刺激;音及び/又はにおいの刺激;酸素濃度が薄くなることによる酸欠刺激等が挙げられ、これらの人混み環境特有の刺激が、頭痛、めまい、倦怠感、及び/又は疲労感等の不調(以下において、「人混み不調」と記載する。)を誘発する。 Specifically, the stimuli brought about by a crowded environment include tension stimulation caused by others approaching one's personal space and, in some cases, even more others coming and going; Stimulation of visual field due to forced movement of eyes due to passing of people; Stimulation of sound and/or smell; Stimulation of oxygen deficiency due to thinning of oxygen concentration, etc. These stimuli unique to crowded environments can cause headaches, headaches, etc. It induces complaints such as dizziness, malaise, and/or fatigue (hereinafter referred to as "crowd complaints").

通常、頓服薬として、頭痛に対しては鎮痛剤が用いられ、めまいに対しては鎮暈剤が用いられる。人混み不調は、人混み環境下に置かれるという所定の条件により誘発される、予測可能な不調であるため、有効な頓服薬があれば望ましい。しかしながら、人混み不調は、頭痛、めまい、倦怠感、疲労感等のうち複数の症状が複合的に生じやすいため、これまでの頓服薬では十分に対応できない。 Usually, analgesics are used to treat headaches, and antidepressants are used to treat dizziness. Crowd disorder is a predictable disorder that is induced by certain conditions such as being in a crowded environment, so it would be desirable to have an effective medication. However, crowd disorder tends to cause a combination of multiple symptoms such as headache, dizziness, malaise, fatigue, etc., and conventional medications cannot be used to adequately treat the condition.

漢方薬の中には、精神科領域において用いられるものがあり、例えば、非特許文献1には、不安及び抑うつに用いられる漢方薬として、ストレスなどで緊張が持続する症状等に対して用いられる、柴胡加竜骨牡蛎湯、四逆散、抑肝散;虚弱で、イライラ、不安、動悸等に対して用いられる桂枝加竜骨牡蛎湯等が記載されており、非特許文献2には、心因性要素が症状を悪化させているめまい等の症状に対して用いられる加味帰脾湯及び加味逍遙散が記載されている。 Some Chinese herbal medicines are used in the field of psychiatry; for example, in Non-Patent Document 1, there is a Chinese herbal medicine used for anxiety and depression called Shiba, which is used for symptoms such as persistent tension due to stress. Kokaryukotsu-oyaito, Shigyakusan, Yokukansan; Keishikaryukotsu-oyaito, which is used to treat irritability, anxiety, palpitations, etc. in the weak, is described, and Non-Patent Document 2 describes Kamikihito and Kamishoyosan are described to be used for symptoms such as dizziness, which are aggravated by sexual factors.

Phil 漢方 2018; 70: 3-8. 医中誌Phil Chinese Medicine 2018; 70: 3-8. Phil 漢方 2014; 47: 20-2. 医中誌Phil Chinese Medicine 2014; 47: 20-2.

漢方薬は多成分系であることから、生体側の複数の作用点に作用することによる複合的な効果が期待できる。しかしながら、一般的に漢方薬は遅効性で、体質改善を目指す目的で用いられるため、人混み不調の症状に対して頓服的に用いられることは想定されていない。また、上述の通り、これまでの頓服薬(西洋薬)では、人混み不調の改善には十分に対応できない。 Since herbal medicine is a multi-component system, compound effects can be expected by acting on multiple points of action on the living body. However, since herbal medicines are generally slow-acting and are used for the purpose of improving one's physical condition, they are not expected to be used casually to treat symptoms of overcrowding. In addition, as mentioned above, conventional medicines (Western medicine) are not sufficient to improve the condition of crowding.

そこで、本発明は、人混み不調を改善できる内服薬を提供することを目的とする。 Therefore, an object of the present invention is to provide an internal medicine that can improve crowd discomfort.

本発明者は、鋭意検討を行ったところ、苓桂朮甘湯が、人混み不調を改善できることを新たに見出した。本発明は、この知見に基づいて、更に検討を重ねることにより完成したものである。 After conducting extensive research, the inventors of the present invention have newly discovered that Reikeijuakanto can improve the problem of crowding. The present invention was completed through further studies based on this knowledge.

即ち、本発明は、下記に掲げる態様の発明を提供する。
項1. 苓桂朮甘湯エキスを含有する、人混み不調改善薬。
項2. 人混み環境で誘発される、頭痛、めまい、倦怠感、及び/又は疲労感を改善するために用いられる、項1に記載の人混み不調改善薬。
項3. 満員車両での乗車により誘発される不調を改善するために用いられる、項1又は2に記載の人混み不調改善薬。
項4. 人混み環境に晒される6時間以内に服用する、項1~3のいずれかに記載の人混み不調改善薬。
That is, the present invention provides the inventions of the following aspects.
Item 1. An anti-crowd medicine that contains Reikeijuu Kanto extract.
Item 2. Item 2. The crowd-related disorder improving drug according to item 1, which is used to improve headache, dizziness, malaise, and/or fatigue induced in a crowded environment.
Item 3. Item 2. The drug for improving crowd discomfort according to item 1 or 2, which is used to improve discomfort induced by riding in a crowded vehicle.
Item 4. The crowd-related disorder improving drug according to any one of Items 1 to 3, which is taken within 6 hours of exposure to a crowded environment.

本発明によれば、人混み不調を改善できる内服薬が提供される。 According to the present invention, an oral medicine that can improve crowd disorder is provided.

本開示の人混み不調改善薬は、苓桂朮甘湯エキスを含有し、人混み不調の改善に用いられることを特徴とする。以下、本開示の人混み不調改善薬について詳述する。本明細書において、2つの数値と「~」とにより示される数値範囲は、当該2つの数値を下限値及び上限値として含むものとする。例えば、2~15重量%との表記は、2重量%以上15重量%以下を意味する。 The medicine for improving crowd discomfort of the present disclosure is characterized in that it contains Reikeijukanto extract and is used for improving crowd anxiety. Hereinafter, the medicine for improving crowd disorder of the present disclosure will be described in detail. In this specification, a numerical range indicated by two numerical values and "~" includes the two numerical values as the lower limit and upper limit. For example, the expression 2 to 15% by weight means 2% by weight or more and 15% by weight or less.

苓桂朮甘湯エキス
苓桂朮甘湯の漢方処方としては、「新 一般用漢方処方の手引き」(合田 幸広・袴塚 高志監修、日本漢方生薬製剤協会編集、株式会社じほう発行)に記載されている漢方処方が好ましく、具体的には、ブクリョウ、ビャクジュツ(ソウジュツも可)、ケイヒ、及びカンゾウからなる混合生薬が挙げられ、好ましくは、ブクリョウ、ソウジュツ、ケイヒ、及びカンゾウからなる混合生薬が挙げられる。また、苓桂朮甘湯には、漢方生薬調査会により定められた「漢方製剤の基本的取扱い方針」に規定されるように、現在繁用されている漢方関係の書簡に記載されている混合生薬(漢方処方)が包含される。
The Chinese herbal prescription for Reikei-Shuu-Akanto Extract Reikei-Shuu-Akanto is based on the Chinese herbal medicines listed in the "New Guide to Prescribing Traditional Chinese Herbal Medicine" (supervised by Yukihiro Goda and Takashi Hakamazuka, edited by the Japan Traditional Chinese Medicine Preparation Association, published by Jiho Co., Ltd.). Prescriptions are preferred, and specific examples include mixed herbal medicines consisting of sagebrush, sandalwood (soujutsu is also acceptable), cinnamon bark, and licorice. Preferably, mixed herbal medicines consisting of sagebrush, sageum, keihi, and licorice are exemplified. In addition, Reikeikyukanto is a mixture of herbal medicines that are listed in letters related to herbal medicines that are currently in frequent use, as stipulated in the "Basic Handling Policy for Chinese Herbal Preparations" established by the Kampo Herbal Medicine Investigation Committee. (Chinese herbal prescriptions) are included.

また、苓桂朮甘湯を構成する各生薬の分量としては、ブクリョウ2~6重量部、好ましくは3~6重量部;ビャクジュツ(ソウジュツも可)1~4重量部、好ましくは2~3.5重量部;ケイヒ1~4重量部、好ましくは2~4重量部;カンゾウ0.5~3重量部、好ましくは1~2重量部が挙げられる。 In addition, the amounts of each crude drug constituting Reikeijukanto are 2 to 6 parts by weight, preferably 3 to 6 parts by weight; 1 to 4 parts by weight, preferably 2 to 3.5 parts by weight. Parts by weight: 1 to 4 parts by weight, preferably 2 to 4 parts by weight of cinnamon; 0.5 to 3 parts by weight, preferably 1 to 2 parts by weight of licorice.

本開示で使用される苓桂朮甘湯エキスの製造に供される生薬調合物の好適な例としては、ブクリョウ6重量部、ビャクジュツ(好ましくはソウジュツ)3重量部、ケイヒ4重量部、及びカンゾウ2重量部が挙げられる。 Suitable examples of the crude drug formulation used in the production of the Reikeijukanto extract used in the present disclosure include 6 parts by weight of Bukryō, 3 parts by weight of sandalwood (preferably sojutsu), 4 parts by weight of cinnamon bark, and 2 parts by weight of licorice. Examples include parts by weight.

苓桂朮甘湯のエキスの形態としては、軟エキス等の液状のエキス、及び固形状の乾燥エキス末のいずれであってもよい。 The form of the extract of Reikeijuakanto may be either a liquid extract such as a soft extract, or a solid dry extract powder.

苓桂朮甘湯の液状のエキスは、苓桂朮甘湯処方に従った混合生薬を抽出処理し、得られた抽出液を必要に応じて濃縮することにより得ることができる。また、苓桂朮甘湯の乾燥エキス末は、液状のエキスを乾燥処理することにより得ることができる。 A liquid extract of Reikeijuakanto can be obtained by extracting a mixed herbal medicine according to the recipe of Reikeijuakanto and concentrating the obtained extract as necessary. Moreover, the dried extract powder of Reikeijukanto can be obtained by drying the liquid extract.

苓桂朮甘湯のエキスの製造において、抽出処理に使用される抽出溶媒としては、特に限定されず、水又は含水エタノールが挙げられる。苓桂朮甘湯の抽出処理としては、特に限定されないが、例えば、苓桂朮甘湯に含まれる生薬の総重量(乾燥重量換算)に対して、5~15倍量程度の抽出溶媒で抽出した後、1/2容量になるまで濃縮し、固形分を除いたものを、苓桂朮甘湯の液状エキスとして得る方法が挙げられる。また、この液状エキスを乾燥処理に供することにより、苓桂朮甘湯の乾燥エキス末が得られる。乾燥処理としては、特に限定されず、公知の方法を用いればよく、例えば、スプレードライ法、及びエキスの濃度を高めた軟エキスに適当な吸着剤(例えば無水ケイ酸、デンプン等)を加えて吸着末とする方法等が挙げられる。 In the production of the extract of Reikeijuakanto, the extraction solvent used in the extraction process is not particularly limited, and includes water and aqueous ethanol. The extraction process for Reikeijuakanto is not particularly limited, but for example, after extraction with an extraction solvent of about 5 to 15 times the total weight (in terms of dry weight) of the herbal medicines contained in Reikeijuakanto. , a method of concentrating to 1/2 volume and removing the solid content is obtained as a liquid extract of Reikeijukanto. Further, by subjecting this liquid extract to a drying treatment, a dry extract powder of Reikeijukanto can be obtained. The drying process is not particularly limited, and any known method may be used, such as spray drying or adding an appropriate adsorbent (for example, silicic anhydride, starch, etc.) to a soft extract with increased concentration. Examples include a method of making an adsorbed powder.

本開示において苓桂朮甘湯としてエキスを使用する場合、前述の方法で調製したエキスを使用してもよいし、市販されるものを使用してもよい。 In the present disclosure, when an extract is used as Reikeijukanto, an extract prepared by the method described above may be used, or a commercially available extract may be used.

本開示の人混み不調改善薬において、苓桂朮甘湯エキスの含有量としては、本開示の効果を奏する限り特に限定されないが、苓桂朮甘湯エキスの乾燥エキス末量換算で、通常5~100重量%、好ましくは10~90重量%、より好ましくは20~80重量%、更に好ましくは30~70重量%が挙げられる。なお、本開示において、苓桂朮甘湯の乾燥エキス末量換算とは、苓桂朮甘湯の乾燥エキス末を使用する場合にはそれ自体の量であり苓桂朮甘湯の液状のエキスを使用する場合には、溶媒を除去した残量に換算した量である。また、苓桂朮甘湯の乾燥エキス末が、製造時に添加される吸着剤等の添加剤を含む場合は、当該添加剤を除いた量である。 In the medicine for improving crowd disorder of the present disclosure, the content of Reikei-Kuan-to extract is not particularly limited as long as it achieves the effects of the present disclosure, but it is usually 5 to 100% by weight in terms of dry extract powder of Rei-Kei-Kuan-to extract. %, preferably 10 to 90% by weight, more preferably 20 to 80% by weight, still more preferably 30 to 70% by weight. In addition, in the present disclosure, the converted amount of dry extract powder of Reikeijuu Kanto is the amount itself when using the dry extract powder of Reikeijuu Kanto; In some cases, it is the amount converted to the remaining amount after removing the solvent. In addition, if the dried extract powder of Reikeijukanto contains additives such as adsorbents added during production, the amount is the amount excluding the additives.

その他の成分
本開示の人混み不調改善薬は、苓桂朮甘湯エキス単独からなるものであってもよく、製剤形態に応じた添加剤及び/又は基剤を含んでいてもよい。このような添加剤及び基剤としては、薬学的に許容されることを限度として特に制限されないが、例えば、賦形剤、結合剤、崩壊剤、滑沢剤、等張化剤、可塑剤、分散剤、乳化剤、溶解補助剤、湿潤化剤、安定化剤、懸濁化剤、粘着剤、コーティング剤、光沢化剤、水、油脂類、ロウ類、炭化水素類、脂肪酸類、高級アルコール類、エステル類、水溶性高分子、界面活性剤、金属石鹸、低級アルコール類、多価アルコール、pH調整剤、緩衝剤、酸化防止剤、紫外線防止剤、防腐剤、矯味剤、香料、粉体、増粘剤、色素、キレート剤等が挙げられる。これらの添加剤は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。また、これらの添加剤及び基剤の含有量については、使用する添加剤及び基剤の種類、人混み不調改善薬の製剤形態等に応じて適宜設定される。
Other Ingredients The medicine for improving crowd disorder of the present disclosure may consist of the Reikeikai Kanto extract alone, or may contain additives and/or bases depending on the formulation form. Such additives and bases are not particularly limited as long as they are pharmaceutically acceptable, but include, for example, excipients, binders, disintegrants, lubricants, tonicity agents, plasticizers, Dispersants, emulsifiers, solubilizing agents, wetting agents, stabilizers, suspending agents, adhesives, coating agents, brightening agents, water, oils and fats, waxes, hydrocarbons, fatty acids, higher alcohols , esters, water-soluble polymers, surfactants, metal soaps, lower alcohols, polyhydric alcohols, pH adjusters, buffers, antioxidants, ultraviolet inhibitors, preservatives, flavorings, fragrances, powders, Examples include thickeners, dyes, chelating agents, and the like. These additives may be used alone or in combination of two or more. Further, the contents of these additives and bases are appropriately set depending on the types of additives and bases used, the formulation form of the crowd-congestion disorder improving drug, and the like.

また、本開示の人混み不調改善薬は、苓桂朮甘湯エキスの他に、必要に応じて、他の栄養成分及び/又は薬理成分を含有していてもよいし、含有していなくてもよい。このような栄養成分及び薬理成分としては、薬学的に許容されることを限度として特に制限されないが、例えば、制酸剤、健胃剤、消化剤、整腸剤、鎮痙剤、粘膜修復剤、抗炎症剤、収れん剤、鎮吐剤、鎮咳剤、去痰剤、消炎酵素剤、鎮静催眠剤、抗ヒスタミン剤、カフェイン類、強心利尿剤、抗菌剤、血管収縮剤、血管拡張剤、局所麻酔剤、生薬エキス(苓桂朮甘湯エキス以外)、ビタミン類、メントール類等が挙げられる。これらの栄養成分及び/又は薬理成分は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。また、これらの成分の含有量については、使用する成分の種類、人混み不調改善薬の製剤形態等に応じて適宜設定される。好ましくは、本開示の人混み不調改善剤は、苓桂朮甘湯エキスの他に、栄養成分及び薬理成分を含有しない。 In addition, the medicine for improving crowd disorder of the present disclosure may or may not contain other nutritional components and/or pharmacological components, as necessary, in addition to the Reikeijuu Kanto extract. . Such nutritional and pharmacological ingredients are not particularly limited as long as they are pharmaceutically acceptable, but include, for example, antacids, stomachic agents, digestive agents, intestinal regulation agents, antispasmodics, mucosal repair agents, anti-inflammatory agents, and astringents. agents, antiemetics, antitussives, expectorants, anti-inflammatory enzymes, sedative-hypnotics, antihistamines, caffeine, cardiotonic diuretics, antibacterial agents, vasoconstrictors, vasodilators, local anesthetics, herbal extracts (Reikeijukanto) (other than extracts), vitamins, menthol, etc. These nutritional components and/or pharmacological components may be used alone or in combination of two or more. Further, the content of these components is appropriately set depending on the type of components used, the formulation form of the crowd-congestion disorder alleviating drug, and the like. Preferably, the crowd disorder improving agent of the present disclosure does not contain any nutritional components or pharmacological components in addition to the Reigui Gakuanto extract.

製剤形態
本開示の人混み不調改善薬の製剤形態については、経口投与が可能であることを限度として特に制限されないが、例えば、散剤、細粒剤、顆粒剤(ドライシロップを含む)、錠剤、丸剤、カプセル剤(軟カプセル剤、硬カプセル剤)等の固形状製剤;ゼリー剤等の半固形状製剤;液剤、懸濁剤、シロップ剤等の液状製剤が挙げられる。これらの製剤形態の中でも、含有成分の安定性及び携帯性等の観点から、好ましくは固形状製剤が挙げられる。
Formulation The form of the preparation of the crowd-congestion disorder improving drug of the present disclosure is not particularly limited as long as it can be administered orally, but examples include powders, fine granules, granules (including dry syrup), tablets, and pills. , solid preparations such as capsules (soft capsules, hard capsules); semi-solid preparations such as jellies; and liquid preparations such as solutions, suspensions, and syrups. Among these formulations, solid formulations are preferred from the viewpoints of stability of the ingredients contained, portability, and the like.

本開示の人混み不調改善薬を前記製剤形態に調製するには、苓桂朮甘湯エキス、並びに必要に応じて添加される添加剤、基剤、栄養成分及び/又は薬理成分を用いて、医薬分野で採用されている通常の製剤化手法に従って製剤化すればよい。 In order to prepare the crowd-congestion disorder improving drug of the present disclosure into the above-mentioned formulation form, it is possible to prepare the drug in the pharmaceutical field by using the Reikeikyukanto extract and additives, bases, nutritional ingredients and/or pharmacological ingredients added as necessary. It may be formulated according to the usual formulation method employed in .

用途
本開示の人混み不調改善薬は、人混み不調の改善を目的として用いられる。人混み不調は、満員車両(例えば、満員電車、満員バス等)内、繁華街、イベント会場等の、人が密集している環境に晒されることによって誘発される不調である。
Uses The drug for improving crowd anxiety of the present disclosure is used for the purpose of improving crowd anxiety. Crowd disorder is a disorder induced by exposure to environments where people are crowded, such as in crowded vehicles (for example, crowded trains, crowded buses, etc.), downtown areas, event venues, etc.

人混み不調の例としては、例えば、自らのパーソナルスペース内に他人が接近し、場合によっては更に他人が行き交うことによる緊張刺激;多くの他人が視界に入り、且つ場合によっては更に他人が行き交うことで視線の動きを強要されることによる視界刺激;音及び/又はにおいの刺激;並びに/若しくは、酸素濃度が薄くなることによる酸欠刺激等の、人混み環境に特有の刺激により誘発される不調が挙げられる。 Examples of crowd disorder include, for example, tension caused by other people approaching one's personal space, and in some cases even more others coming and going; many others coming into view, and in some cases even more others coming and going Disorders induced by stimuli specific to crowded environments, such as visual stimulation due to forced eye movement; sound and/or smell stimulation; and/or oxygen deficiency stimulation due to thinning of oxygen concentration, are listed. It will be done.

人混み不調のより具体的な例としては、頭痛、めまい、倦怠感、及び/又は疲労感等が挙げられる。 More specific examples of crowd discomfort include headache, dizziness, malaise, and/or fatigue.

これらの人混み不調の中でも、人混み不調の改善効果をより一層高める観点から、好ましくは、満員車両内の環境に特有の刺激によってもたらされる不調が挙げられ、より好ましくは、満員車両内の環境に特有の刺激によってもたらされる、頭痛、めまい、倦怠感、及び/又は疲労感が挙げられる。 Among these crowd disorders, from the viewpoint of further increasing the effect of improving crowd disorder, it is preferable to mention disorders brought about by stimuli specific to the environment inside a crowded car, and more preferably, disorders caused by stimuli specific to the environment inside a crowded car. headache, dizziness, malaise, and/or fatigue caused by stimulation of

人混み不調に晒される時間帯については特に限定されず、例えば、6時以降12時経過前(朝の満員電車に乗車する時間帯を含む。)、12時以降17時経過前、17時以降20時経過前(夕方の満員電車に乗車する時間帯を含む。)、20時以降24時経過前等が挙げられ、好ましくは17時以降20時経過前が挙げられる。 There are no particular restrictions on the time periods during which you are exposed to crowd congestion, such as after 6:00 and before 12:00 (including the time when boarding a crowded train in the morning), after 12:00 and before 17:00, after 17:00 and before 8:00 p.m. Examples include before the passage of time (including the time when boarding a crowded train in the evening), after 20:00 and before 24:00, and preferably after 17:00 and before 20:00.

用量・用法
本開示の人混み不調改善薬は経口投与によって使用される。本開示の人混み不調改善薬の用量については、投与対象者の年齢、性別、体質、症状の程度等に応じて適宜設定される。例えば、ヒト1人に対して1日当たり、苓桂朮甘湯エキスの乾燥エキス末量換算で0.3~2g、好ましくは0.6~1.5gとなる量で、1日1~3回、人混み環境に晒される回数に応じて服用できる。また、例えば、ヒト1人に対して1回当たり、苓桂朮甘湯エキスの乾燥エキス末量換算で0.1~1g程度、好ましくは0.2~0.75g、より好ましくは0.3~0.5gとなる量で、1日1~3回、好ましくは2回服用できる。
Dosage/Usage The crowding disorder improving drug of the present disclosure is used by oral administration. The dose of the crowd-congestion disorder improving drug of the present disclosure is appropriately set according to the age, sex, constitution, severity of symptoms, etc. of the subject to be administered. For example, 1 to 3 times a day in an amount of 0.3 to 2 g, preferably 0.6 to 1.5 g, in terms of dry extract final amount of Reikeikai Kanto extract per person per day; You can take it depending on how many times you are exposed to crowded environments. Further, for example, the dry extract powder amount of Reikeikai Kanto extract per person is about 0.1 to 1 g, preferably 0.2 to 0.75 g, and more preferably 0.3 to 1 g per person. The amount of 0.5g can be taken 1 to 3 times a day, preferably 2 times a day.

服用タイミングについては、特に制限されず、食前、食後、又は食間のいずれであってもよい。本開示の人混み不調改善薬は即効性があるため、頓服薬として用いることができ、例えば、人混み不調を予防することを目的として、人混み環境に晒される6時間以内、好ましくは5時間以内、より好ましくは4時間以内、さらに好ましくは3時間以内に服用できる。 The timing of administration is not particularly limited, and may be taken before meals, after meals, or between meals. The medicine for improving crowd anxiety of the present disclosure has immediate effect, so it can be used as an as-needed medicine, for example, for the purpose of preventing crowd anxiety, within 6 hours, preferably within 5 hours of being exposed to a crowd environment. Preferably, it can be taken within 4 hours, more preferably within 3 hours.

以下、本発明を実施例により具体的に説明するが、本発明はこれらの実施例に限定されるものではない。 EXAMPLES Hereinafter, the present invention will be specifically explained with reference to Examples, but the present invention is not limited to these Examples.

苓桂朮甘湯エキス顆粒の製造
原料生薬を、ブクリョウ6重量部、ソウジュツ3重量部、ケイヒ4重量部、及びカンゾウ2重量部の割合で用い、これらを刻んだ後、水12倍重量を用いて約100℃で1時間抽出し、遠心分離して抽出液を得、減圧下で濃縮してスプレードライヤーを用いて乾燥し、苓桂朮甘湯エキス末を得た。得られた苓桂朮甘湯エキス末は、原料生薬混合物15g当たり1.5gであった。なお、スプレードライヤーによる乾燥は、抽出液を回転数10000rpmのアトマイザーに落下させ、150℃の空気の熱風を供給して行った。さらに、得られた苓桂朮甘湯エキス末を用いて顆粒製剤を調製した。1日当たりの苓桂朮甘湯エキス末の服用量は0.75g、1回当たりの苓桂朮甘湯エキス末の服用量は0.325gとした。
The raw materials for the production of Reikeikakuanto extract granules are used in the proportions of 6 parts by weight of Bukryō, 3 parts by weight of Soju, 4 parts by weight of cinnamon bark, and 2 parts by weight of licorice. The extract was extracted at about 100° C. for 1 hour, centrifuged to obtain an extract, concentrated under reduced pressure, and dried using a spray dryer to obtain a powdered Rei Guiju Ganto extract. The amount of the obtained Reikeijuu Kanto extract powder was 1.5 g per 15 g of the raw herbal medicine mixture. Note that drying with a spray dryer was performed by dropping the extract into an atomizer with a rotational speed of 10,000 rpm, and supplying hot air at 150°C. Furthermore, a granule preparation was prepared using the obtained Reikeijukanto extract powder. The daily dose of Reikeijuu Kanto extract powder was 0.75 g, and the dose of Rei Keijuu Kanto extract powder per dose was 0.325 g.

試験例
人混み不調を訴える男女8名を被験対象とした。これらの被験対象は、満員電車に乗車した時に、頭痛、めまい、倦怠感、及び/又は疲労感の不調(パニック発作は含まない)を感じていた。
Experimental Example The subjects were eight men and women who complained of discomfort with crowds. These test subjects experienced complaints of headache, dizziness, fatigue, and/or fatigue (not including panic attacks) when boarding the crowded train.

朝の満員電車及び夕方の満員電車(いずれも混雑度が同程度となる時間帯を選択した。)それぞれに乗車する3時間前(食前又は食間)に、苓桂朮甘湯エキス0.375g(乾燥エキス換算量)となる用量の顆粒剤を服用した。 Three hours before boarding a crowded train in the morning and a crowded train in the evening (we selected times when the level of congestion was the same for both) (before or between meals), we added 0.375 g of Ring Guijuu Sweet Tang Extract (dried). The patient took the granules at a dose equivalent to the extract equivalent amount.

1回の服用による人混み不調の改善効果について、人混み不調の総合的な改善効果、並びに、人混み不調のうち訴えがある各々の不調(具体的には、頭痛、倦怠感、疲労感、めまい)の改善効果について、「感じた」「どちらかといえば感じた」「どちらともいえない」「どちらかといえば感じなかった」「感じなかった」のいずれかの評価にて回答を得た。それぞれの評価で回答した人数の比率(%)を表1に示す。また、表1では、「感じた」「どちらかといえば感じた」と評価した人数の合計の比率(%)を有効ポイントとして併せて示した。 Regarding the improvement effect of crowd-related disorder after one dose, we will examine the overall improvement effect of crowd-related disorder as well as the improvement of each complaint of crowd-related disorder (specifically, headache, malaise, fatigue, dizziness). Regarding the improvement effect, responses were received as ``I felt it'', ``I felt it somewhat'', ``I can't say either way'', ``I didn't feel it at all'', or ``I didn't feel it.'' Table 1 shows the ratio (%) of the number of people who responded for each evaluation. Table 1 also shows the ratio (%) of the total number of people who rated "I felt it" or "I felt it rather" as valid points.

Figure 2024029735000001
Figure 2024029735000001

表1に示す通り、苓桂朮甘湯エキスを乗車前に服用することで、満員電車に乗った時に誘発される人混み不調の様々な症状が改善され、人混み不調の総合的な改善効果について、高い有効ポイントが得られた。特に、当該不調の中でも、夕方における満員電車に乗った時に誘発される人混み不調については、人混み不調の総合的な改善効果について有効ポイント100%が達成され、極めて高い改善効果が得られた。 As shown in Table 1, by taking Reikeikakuanto extract before boarding a train, various symptoms of crowd discomfort caused by riding on a crowded train are improved, and the overall improvement effect for crowd anxiety is high. Valid points were obtained. In particular, among the complaints, 100% of effective points were achieved for the overall improvement effect of crowd disorder, which is induced by riding on a crowded train in the evening, and an extremely high improvement effect was obtained.

Claims (4)

苓桂朮甘湯エキスを含有する、人混み不調改善薬。 An anti-crowd medicine that contains Reikeijuu Kanto extract. 人混み環境で誘発される、頭痛、めまい、倦怠感、及び/又は疲労感を改善するために用いられる、請求項1に記載の人混み不調改善薬。 2. The crowd-related disorder improving drug according to claim 1, which is used to improve headache, dizziness, malaise, and/or fatigue induced in a crowded environment. 満員車両での乗車により誘発される不調を改善するために用いられる、請求項1に記載の人混み不調改善薬。 The drug for improving crowd discomfort according to claim 1, which is used to improve discomfort induced by riding in a crowded vehicle. 人混み環境に晒される6時間以内に服用する、請求項1に記載の人混み不調改善薬。 The crowd-related disorder improving drug according to claim 1, which is taken within 6 hours of being exposed to a crowded environment.
JP2022201857A 2022-12-19 2022-12-19 Medicine for alleviating health issues caused by crowds Pending JP2024029735A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022201857A JP2024029735A (en) 2022-12-19 2022-12-19 Medicine for alleviating health issues caused by crowds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2022201857A JP2024029735A (en) 2022-12-19 2022-12-19 Medicine for alleviating health issues caused by crowds

Publications (1)

Publication Number Publication Date
JP2024029735A true JP2024029735A (en) 2024-03-06

Family

ID=90104957

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022201857A Pending JP2024029735A (en) 2022-12-19 2022-12-19 Medicine for alleviating health issues caused by crowds

Country Status (1)

Country Link
JP (1) JP2024029735A (en)

Similar Documents

Publication Publication Date Title
Akhondzadeh et al. Crocus sativus L. in the treatment of mild to moderate depression: a double‐blind, randomized and placebo‐controlled trial
Mills et al. Herbal medicines in pregnancy and lactation: an evidence-based approach
Mirabi et al. Effects of valerian on the severity and systemic manifestations of dysmenorrhea
Kaur et al. Herbal medicines: possible risks and benefits
US8021701B1 (en) Composition to retard the onset of symptoms of alzheimer's disease
JP2011148727A (en) Beauty set for improving wrinkle and beauty method using the same
Baharara et al. The effects of ivy (Hedera helix) on respiratory problems and cough in humans: a review
Prasad et al. Role of herbs in the management of asthma
JP2012508772A (en) Compositions and methods for mitigating reduced salivary secretion and providing oral comfort
US5897864A (en) Method for treating sexual dysfunction disorders with compositions containing ginkgo biloba
Zarghami et al. Antidepressant effect of Asperugo procumbens L. in comparison with fluoxetine: a randomized double blind clinical trial
Murali et al. Plant-based formulation for bronchial asthma: a controlled clinical trial to compare its efficacy with oral salbutamol and theophylline
Bartels et al. Herbal and related remedies
JP2024029735A (en) Medicine for alleviating health issues caused by crowds
CN106237268B (en) It is a kind of to treat schizoid pharmaceutical composition and its application
JP2007131592A (en) Prophylactic and/or therapeutic composition for pollinosis and/or house dust allergy comprising propolis
CN100370973C (en) Traditional Chinese medicinal prepn. for treating obstruction of qi in the chest
JP2021119123A (en) Internal medicine for improving eye focus adjustment
JP7385990B2 (en) Hypersomnia treatment
CN112826901A (en) Medicine for quickly relieving senile dementia symptoms
JP7498993B1 (en) A composition that improves menstrual symptoms such as depression, lack of concentration, decreased motivation to socialize and engage in daily activities, autonomic nervous system disorders, pain, control, and poor quality of sleep.
JP2024031740A (en) Medicine for alleviating health issues in evening
Givens et al. Valerian
JP2024017078A (en) Muscle water content improving agent
RU2189243C1 (en) Compositions "ginrosin" showing general tonic and adaptogenic effect